ptx-100 presentation, page-4

Re trial. My memory was the anticipated path would be:
- likely recruit 2x patients per month
- aiming for 10 patients
- split 7 internal Lymphoma, 3 skin lymphoma

Length of time trial to run for was not, as far as I could remember, explicitly stated. What was stated was that average length of response to "current standard of care treatment" was 4 months. some respond for longer, some shorter.

And a follow up comment was made that, due to average length of response to current treatment being 4 months, that (to paraphrase), it would not take a lengthy trial to determine whether the drug was working

Implies, to me:
- if all goes to plan there will be 10 patients recruited from Oct, 2021. Through to Feb 2022.
- If last patients recruited Feb 2022. Six months after Feb 2022 is August 2022. Add on time to analyse data.

It will take a while before there is meaningful data that could be shared. At most out-rageously optimistic - End Q1 2022. Slighlty more realistic but still extremely optimistic - end Q2 2022. Starting to feel like it is realistic optimism - end Q3 2022.